LONDON, June 11 (Reuters) - Britain's MHRA medicine
regulator is considering precautionary advice for people with a
history of capillary leak syndrome but does not see a causal
link with AstraZeneca's COVID-19 vaccine after the EU said it
was a rare side effect of the shot.
MHRA Chief Executive June Raine said that two of eight
reports of capillary leak syndrome following AstraZeneca
vaccination were in people with a history of the condition, and
40 million doses of the vaccine had been given.
"The incidence of these reports is lower than the number of
cases expected to occur by chance in the absence of vaccination
of this extremely rare condition and the current evidence does
not suggest that capillary leak syndrome is caused by the
COVID-19 Vaccine AstraZeneca," she said.
"Whether or not a precautionary advice is warranted for
patients who have previously experienced capillary leak syndrome
is currently being carefully considered by the MHRA as well as
the independent Commission on Human Medicines’ COVID-19
Benefit/Risk Expert Working Group."
(Reporting by Alistair Smout; editing by Sarah Young)